Most available mTOR inhibitors that have been rigorously tested for clinical use are rapamycin derivatives; however, the performance of rapamycin and its analogs has been undistinguished despite isolated successes in subsets of cancer,[6] suggesting that the full therapeutic potential of targeting mTOR is yet to be exploited. Here, MTOR is linked to cancer.